Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs 2008 Feb;9(2):210-25
Date
02/05/2008Pubmed ID
18246524Scopus ID
2-s2.0-38849190721 (requires institutional sign-in at Scopus site) 35 CitationsAbstract
Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and skin structure infections and hospital-acquired pneumonia. Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing.
Author List
Peppard WJ, Schuenke CDAuthor
William J. Peppard PharmD Trauma/Surgical Critical Care Pharmacist in the Pharmacy department at Froedtert HospitalMESH terms used to index this publication - Major topics in bold
AnimalsAnti-Bacterial Agents
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Evaluation, Preclinical
Folic Acid Antagonists
Humans
Methicillin Resistance
Molecular Structure
Patents as Topic
Pyrimidines
Staphylococcal Infections
Structure-Activity Relationship